Flourishing Global Adult Epilepsy Market

The promising recently approved antiepileptic drugs that provide efficacy for treatment resistant patients, and improved safety profiles will increase the global adult epilepsy market sales to $8.35bn by 2023.

The adult epilepsy market is expected to grow from $5.82bn in 2020 to $8.35bn by 2030 across the seven major markets at a compound annual growth rate (CAGR) of 3.7%, according to Global Data, a leading data and analytics company.

The company’s latest report reveals that the launches of several recently approved products, including SK Biopharmaceuticals’ Xcopri, UCB’s Nayzilam, Neurelis’ Valtoco, Zogenix’s Fintepla, and GW Pharmaceuticals’ Epidiolex, are expected to drive the market growth.

Fits | Epilepsy | Convulsions - Causes Symptoms Diagnosis Treatment FAQs
Fits or convulsions or Epilepsy is characterized by recurrent, involuntary seizures and is described as a chronic neurological disorder

‘Recent drug launches will induce global adult epilepsy market to reach $8.35bn sales by 2023.’

Philippa Salter, Neurology Analyst at Global Data, comments: “Having demonstrated strong efficacy in clinical trials, the recent launch of Xcopri will be a strong driver of growth in the adult epilepsy market, particularly during the first half of the forecast period. Global Data forecasts peak sales for Xcopri of $1.47bn in 2027”.

GlobalData recognizes that continued generic erosion will be a significant barrier to growth in the adult epilepsy market.

The patent expiries of several key products, including the blockbuster drugs Xcopri in 2027 and Vimpat in 2022, will significantly negatively impact the sales.

Epilepsy can be Treated by the �Mozart Effect�
Mozart effect contributes to a reduction in the epileptic activity of the brain through the special acoustic (physical) properties within the music.

Azurity Pharmaceuticals’ topiramate (ET-101) and zonisamide (ET-104), Eisai’s lorcaserin, Marinus Pharmaceuticals’ ganaxolone, and Takeda Pharmaceutical/Ovid Therapeutics’ soticlestat are expected to launch during the forecast period.

Ganaxolone is the only expected to significantly impact the adult market with the other products predominantly targeted at the paediatric epilepsy population. So, they are not expected to generate enough sales to overcome the decline in sales due to the generic erosion of key products in the market.

New Potential Target Found For Treating Epilepsy
Drug resistance epilepsy can be treated by using a new therapeutic strategy that suppress changes in the pH of the astrocytes that accompany the neuronal activity.

Salter adds: “Ganaxolone has shown extremely promising results for treating status epilepticus in clinical trials and key opinion leaders (KOLs) interviewed by GlobalData believe it has the potential to significantly alter how status epilepticus is treated in the future”.

Despite a large number of antiepileptic drugs (AEDs) available on the market, and the promising recently approved drugs such as Xcopri, the need for drugs that provide efficacy for treatment resistant patients, and for drugs with improved safety profiles are incomplete.

No Link Between Antiseizure Drugs and Cognitive Problems
Cognitive outcomes among kids do not vary with antiseizure medications taken by their mothers during pregnancy.

Furthermore, many of the drugs currently used allow for symptomatic relief or prevention of seizures, and KOLs have highlighted that curative or disease-modifying therapies will also be highly sought in the epilepsy market.

Source-Medindia